Loading...
Market
Story
FDA Approves Eli Lilly's EBGLYSS™ Eczema Drug for Adults and Children on Friday
Sep 13, 2024, 11:10 PM
Eli Lilly announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its eczema drug, EBGLYSS™ (lebrikizumab-lbkz), for use in adults and children aged 12 years and older. The drug is intended to treat moderate-to-severe atopic dermatitis, a condition characterized by itchy, dry, and scaly skin. This approval marks a significant advancement for individuals suffering from eczema, offering a new treatment option for a diverse group of patients.
View original story
Similar markets
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%